Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML

NCT04167917 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT04167917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04167917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1
Overall status
Completed
Start date
January 6, 2021
Completion date
April 24, 2025
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes